ReNeuroGen LLC
Elm Grove, WI · Biotech · Private
KYC (N-acetyl-lysyltyrosylcysteine amide), a bioengineered tripeptide therapeutic inhibitor of myeloperoxidase for treating bronchopulmonary dysplasia in preterm infants
- Grants
- $5.8M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A Novel Myeloperoxidase Inhibitor for Treating Multiple Sclerosis | $285,790 | |
| Federal grant | Department of Health and Human Services · Phase I · KYC Reduces Vasculopathy in Sickle Cell Disease | $274,490 | |
| Federal grant | Department of Health and Human Services · Phase I · KYC Reduces Vasculopathy in Sickle Cell Disease | $274,490 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1,008,564 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1,008,564 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1,861,772 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain | $1,045,688 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2965 | Regenicin, Inc. | — | $4.5M |
| 2966 | PHENOTARGET BIOSCIENCES INC | — | — |
| 2967 | 42Bio, LLC | — | — |
| 2968 | ReNeuroGen LLC | — | — |
| 2969 | The NanoMedicines Innovation Network | — | — |
| 2970 | Kartos Therapeutics | — | — |
| 2971 | CANCURE LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Systems Chemico-Pharmacology Drugs and Methods of Useapplication
- Systems Chemico-pharmacology Drugs And Methods Of Useapplication
- Systems Chemico-pharmacology Drugs And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.